Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cetuximab + carboplatin + vinorelbine in platinum-resistant head and neck cancer
2009-013878-40Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in head and neck cancer (HNC) and head and neck squamous cell carcinoma (HNSCC), sponsored by University Hospital Odense. Primary endpoint: Primary objective. Started Aug 2009; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck cancer (HNC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2009-013878-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013878-40.